How does tigecycline's effectiveness against b fragilis compare to metronidazole?

How does tigecycline perform against B. fragilis in clinical studies?

Tigecycline shows strong activity against B. fragilis, with most isolates inhibited at concentrations of 1–4 mg/L in large surveillance collections. Clinical response rates in complicated intra-abdominal infections reach 80–85 percent when the drug is used as monotherapy.

How does metronidazole compare for the same pathogen?

Metronidazole remains highly active against nearly all B. fragilis strains, with MIC90 values typically below 2 mg/L. In mixed aerobic-anaerobic intra-abdominal infections it is usually paired with a beta-lactam or fluoroquinolone because it lacks reliable coverage of gram-negative aerobes.

What are the key differences in spectrum and dosing?

Tigecycline covers both gram-negative aerobes and anaerobes in a single agent, allowing monotherapy. Metronidazole requires combination therapy for most intra-abdominal cases. Tigecycline is given intravenously twice daily; metronidazole can be dosed orally or intravenously two to three times daily and achieves excellent tissue penetration.

When is each agent preferred in practice?

Tigecycline is often chosen when extended-spectrum beta-lactamase–producing Enterobacterales or multidrug-resistant Acinetobacter are also suspected. Metronidazole plus a carbapenem or piperacillin-tazobactam is favored for severe or hospital-acquired infections where broader anaerobic coverage or lower cost is needed.

Are resistance trends changing the picture?

B. fragilis resistance to metronidazole remains below 5 percent worldwide, but sporadic high-level resistance linked to nim genes has been reported. Tigecycline resistance in B. fragilis is still rare, though MIC creep has been noted in some regions.

When does the tigecycline patent expire?

The composition-of-matter patent for tigecycline expired in 2015 in the United States; generic versions are now widely available.